Restoration of haemoglobin level using hydrodynamic gene therapy with erythropoietin does not alleviate the disease progression in an anaemic mouse model for TGFβ1-induced chronic kidney disease

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Pedersen, Lea ^a   Wogensen, Lise ^a   Marcussen, Niels ^b   Cecchi, Claudia R ^c   Dalsgaard, Trine ^c   Dagnæs Hansen, Frederik ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ERYTHROPOIETIN; HEMOGLOBIN; PLASMID DNA; TRANSFORMING GROWTH FACTOR BETA1; FIBRONECTIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; EPO GENE; GENE OVEREXPRESSION; GLOMERULUS BASEMENT MEMBRANE; HYDRODYNAMICS BASED TRANSFECTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY STRUCTURE; MALE; MOUSE; NONHUMAN; PLASMID; PROTEIN EXPRESSION; ANIMAL; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; GENE THERAPY; GENETICS; KIDNEY; LIVER; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

MURINAE; MUS; MUS MUSCULUS;

ANEMIA; ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ERYTHROPOIETIN; FIBRONECTINS; GENETIC THERAPY; GLOMERULAR BASEMENT MEMBRANE; HEMOGLOBINS; KIDNEY; LIVER; MALE; MICE; MICE, TRANSGENIC; PLASMIDS; RENAL INSUFFICIENCY, CHRONIC; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84934953658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128367     Document Type: Article

References (44)

1. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352: 1011-1023. 352/10/1011 [pii]; doi: 10.1056/NEJMra041809 PMID: 15758012
2. Sharples EJ, Yaqoob MM (2006) Erythropoietin and acute renal failure. Semin Nephrol 26: 325-331. S0270-9295(06)00076-3 [pii]; doi: 10.1016/j.semnephrol.2006.05.010 PMID: 16949472
3. Fried W (1995) Erythropoietin. Annu Rev Nutr 15: 353-377. doi: 10.1146/annurev.nu.15.070195.002033 PMID: 8527225
4. Lombardero M, Kovacs K, Scheithauer BW (2011) Erythropoietin: a hormone with multiple functions. Pathobiology 78: 41-53. 000322975 [pii]; doi: 10.1159/000322975 PMID: 21474975
5. Fisher JW, Koury S, Ducey T, Mendel S (1996) Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 95: 27-32. PMID: 8857934
6. Haase VH (2010) Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol 299: F1-13. ajprenal.00174.2010 [pii]; doi: 10.1152/ajprenal.00174.2010 PMID: 20444740
7. Loeffler I, Ruster C, Franke S, Liebisch M, Wolf G (2013) Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse. Am J Physiol Renal Physiol 305: F911-F918. ajprenal.00643.2012 [pii]; doi: 10.1152/ajprenal.00643.2012 PMID: 23825071
8. Imamura R, Moriyama T, Isaka Y, Namba Y, Ichimaru N, Takahara S, et al. (2007) Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 83: 1371-1379. doi: 10.1097/01.tp.0000264200.38926.70 00007890-200705270-00014 [pii]. PMID: 17519789
9. Teixeira AM, Garrido P, Santos P, Alves R, Parada B, Costa E, et al. (2010) Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure. Ren Fail 32: 1073-1080. doi: 10.3109/0886022X.2010.509897 PMID: 20863212
10. Bellizzi V, Sabbatini M, Fuiano G, Sansone G, Magri P, Uccello F, et al. (1998) The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol Dial Transplant 13: 2210-2215. PMID: 9761499
11. Tanaka T, Nangaku M (2012) Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 318: 1068-1073. S0014-4827(12)00111-5 [pii]; doi: 10.1016/j.yexcr.2012.02.035 PMID: 22414872
12. Nangaku M (2013) Tissue protection by erythropoietin: new findings in a moving field. Kidney Int 84: 427-429. ki2013140 [pii]; doi: 10.1038/ki.2013.140 PMID: 23989353
13. Frenay AR, Ruifrok WP, Bulthuis M, Huitema S, de Boer RA, van GH (2012) Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats. J Renin Angiotensin Aldosterone Syst 13: 232-238. 1470320311432186 [pii]; doi: 10.1177/1470320311432186 PMID: 22282864
14. Fliser D, Haller H (2007) Erythropoietin and treatment of non-anemic conditions - cardiovascular protection. Semin Hematol 44: 212-217. S0037-1963(07)00071-6 [pii]; doi: 10.1053/j.seminhematol.2007.04.008 PMID: 17631185
15. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC (2006) Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 69: 1806-1813. 5000356 [pii]; doi: 10.1038/sj.ki.5000356 PMID: 16598197
16. Wogensen L, Nielsen CB, Hjorth P, Rasmussen LM, Høj Nielsen A, Gross K, et al. (1999) Under control of the Renin-1c promoter, Locally, produced transforming growth factor-β1 induces accumulation of glomerular extracellular matrix in transgenic mice. Diabetes 48: 182-192. PMID: 9892241
17. Krag S, Danielsen CC, Carmeliet P, Nyengaard J, Wogensen L (2005) Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int 68: 2651-2666. PMID: 16316341
18. Zhang G, Budker V, Wolff JA (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 10: 1735-1737. doi: 10.1089/10430349950017734 PMID: 10428218
19. Zhang G, Song YK, Liu D (2000) Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure. Gene Ther 7: 1344-1349. doi: 10.1038/sj.gt.3301229 PMID: 10918507
20. Liu F, Song Y, Liu D (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266. doi: 10.1038/sj.gt.3300947 PMID: 10455434
21. Dagnaes-Hansen F, Holst HU, Sondergaard M, Vorup-Jensen T, Flyvbjerg A, Jensen UB, et al. (2002) Physiological effects of human growth hormone produced after hydrodynamic gene transfer of a plasmid vector containing the human ubiquitin promotor. J Mol Med (Berl) 80: 665-670. doi: 10.1007/s00109-002-0371-1 PMID: 12395151
22. Miao CH, Thompson AR, Loeb K, Ye X (2001) Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 3: 947-957. doi: 10.1006/mthe.2001.0333 S1525-0016(01)90333-8 [pii]. PMID: 11407909
23. Kameda S, Maruyama H, Higuchi N, Nakamura G, Iino N, Nishikawa Y, et al. (2003) Hydrodynamics-based transfer of PCR-amplified DNA fragments into rat liver. Biochem Biophys Res Commun 309: 929-936. S0006291X03016838 [pii]. PMID: 13679063
24. Maruyama H, Higuchi N, Nishikawa Y, Hirahara H, Iino N, Kameda S, et al. (2002) Kidney-targeted naked DNA transfer by retrograde renal vein injection in rats. Hum Gene Ther 13: 455-468. doi: 10.1089/10430340252792585 PMID: 11860712
25. Jakobsen JE, Li J, Kragh PM, Moldt B, Lin L, Liu Y, et al. (2011) Pig transgenesis by Sleeping Beauty DNA transposition. Transgenic Res 20: 533-545. doi: 10.1007/s11248-010-9438-x PMID: 20803249
26. Hojman P, Gissel H, Gehl J (2007) Sensitive and precise regulation of haemoglobin after gene transfer of erythropoietin to muscle tissue using electroporation. Gene Ther 14: 950-959. 3302951 [pii]; doi: 10.1038/sj.gt.3302951 PMID: 17410179
27. Diehl KH, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21: 15-23. doi: 10.1002/jat.727 [pii]. PMID: 11180276
28. Gundersen HJ, Jensen TB, Osterby R (1978) Distribution of membrane thickness determined by lineal analysis. J Microsc 113: 27-43. PMID: 691043
29. Danielsen CC, Andreassen TT (1988) Mechanical properties of rat tail tendon in relation to proximaldistal sampling position and age. J Biomech 21: 207-212. PMID: 3379081
30. Gurtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K, et al. (2013) Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem 433: 105-111. S0003-2697(12) 00512-X [pii]; doi: 10.1016/j.ab.2012.10.010 PMID: 23085117
31. Krag S, Østerby R, Chai Q, Nielsen B, Hermans C, Wogensen L (2000) TGF-β1-induced glomerular disorder is associated with impaired concentrating ability mimicking primary glomerular disease with renal failure in man. Lab Invest 80: 1855-1868. PMID: 11140698
32. Chai Q, Krag S, Chai S, Ledet T, Wogensen L (2003) Localisation and phenotypical characterisation of collagen-producing cells in TGF-beta 1-induced renal interstitial fibrosis. Histochem Cell Biol 119: 267-280. doi: 10.1007/s00418-003-0513-8 PMID: 12684813
33. Kellenberger T, Krag S, Danielsen CC, Wang XF, Nyengaard JR, Pedersen L, et al. (2013) Differential effects of Smad3 targeting in a murine model of chronic kidney disease. Physiological Reports 1.
34. Krag S, Nyengaard JR, Wogensen L (2007) Combined effects of moderately elevated blood glucose and locally produced TGF-beta1 on glomerular morphology and renal collagen production. Nephrol Dial Transplant 22: 2485-2496. gfm229 [pii]; doi: 10.1093/ndt/gfm229 PMID: 17452404
35. Miner JH (1999) Renal basement membrane components. Kidney Int 56: 2016-2024. PMID: 10594777
36. Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P (2014) The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 7: 4. 1755-1536-7-4 [pii]; doi: 10.1186/1755-1536-7-4 PMID: 24678881
37. Sondergaard M, Dagnaes-Hansen F, Flyvbjerg A, Jensen TG (2003) Normalization of growth in hypophysectomized mice using hydrodynamic transfer of the human growth hormone gene. Am J Physiol Endocrinol Metab 285: E427-E432. doi: 10.1152/ajpendo.00573.2002 00573.2002 [pii]. PMID: 12657568
38. Maruyama H, Higuchi N, Nishikawa Y, Kameda S, Iino N, Kazama JJ, et al. (2002) High-level expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med 4: 333-341. doi: 10.1002/jgm.281 PMID: 12112650
39. Jacobs C (1995) Starting r-HuEPO in chronic renal failure: when, why, and how? Nephrol Dial Transplant 10 Suppl 2: 43-47. PMID: 7644105
40. Eschbach JW (1995) The future of r-HuEPO. Nephrol Dial Transplant 10 Suppl 2: 96-109. PMID: 7644114
41. Gong H, Wang W, Kwon TH, Jonassen T, Li C, Ring T, et al. (2004) EPO and alpha-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 66: 683-695. doi: 10.1111/j.1523-1755.2004.00791.x KID791 [pii]. PMID: 15253723
42. Westenfelder C (2002) Unexpected renal actions of erythropoietin. Exp Nephrol 10: 294-298. 65304 [pii];65304 [doi]. PMID: 12381912
43. Nemoto T, Yokota N, Keane WF, Rabb H (2001) Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int 59: 246-251. kid485 [pii]; doi: 10.1046/j.1523-1755.2001.00485.x PMID: 11135077
44. Solling C, Christensen AT, Krag S, Frokiaer J, Wogensen L, Krog J, et al. (2011) Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 55: 185-195. doi: 10.1111/j.1399-6576.2010.02369.x PMID: 21226860